GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained <i>In Vivo</i> Pathway InhibitionAidan G. Gilmartin, Sylvie Laquerre|Clinical Cancer Research|2011Cited by 600
Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemiaMelissa B. Pappalardi, Rab K. Prinjha, Kristen Wong et al.|Nature Cancer|2021Cited by 279
Pemigatinib for Myeloid/Lymphoid Neoplasms with <i>FGFR1</i> RearrangementSrđan Verstovšek, Jason Gotlib, Jean‐Jacques Kiladjian et al.|NEJM Evidence|2025Cited by 7